Pharmacophoric modifications lead to superpotent αvβ3 integrin ligands with suppressed α5β1 activity

Journal of Medicinal Chemistry

Volumn 57, Issue 8, 2014, Pages 3410-3417

  Neubauer, Stefanie ^a,f   Rechenmacher, Florian ^a   Brimioulle, Richard ^a   Di Leva, Francesco Saverio ^b,c   Bochen, Alexander ^a   Sobahi, Tariq R ^d   Schottelius, Margret ^e   Novellino, Ettore ^c   Mas Moruno, Carlos ^a,g   Marinelli, Luciana ^c   Kessler, Horst ^a,d  

^a Munich Center for Integrated Protein Science   (Germany)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f MAX PLANCK INSTITUTE FOR INTELLIGENT SYSTEMS   (Germany)

^g UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 FLUOROBENZAMIDO) 4 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL]BUTANOIC ACID; 3 (4 ISOPROPOXYBENZAMIDO) 4 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL]BUTANOIC ACID; 3 BENZAMIDO 4 [4 [3 [(6 METHYLPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL]BUTANOIC ACID; 3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPAN 1 OL; 4 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL] 3 (4 METHYLPHENYLSULFONAMIDO)BUTANOIC ACID; CILENGITIDE; METHYL 3 [( TERT BUTOXYCARBONYL)AMINO] 4 [4 (3 HYDROXYPROPOXY)PHENYL]BUTANOATE; METHYL 3 [(TERT BUTOXYCARBONYL)AMINO] 4 [4 (3 OXOPROPOXY)PHENYL]BUTANOATE; METHYL 3 [(TERT BUTOXYCARBONYL)AMINO] 4 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL]BUTANOATE; N (4 (HYDROXYAMINO) 1 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL] 4 OXOBUTAN 2 YL) 4 ISOPROPOXYBENZAMIDE; N HYDROXY 4 [4 [3 [(4 METHOXYPYRIDIN 2 YL)AMINO]PROPOXY]PHENYL] 3 [(4 METHYLPHENYL)SULFONAMIDO]BUTANAMIDE; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR;

ARTICLE; BINDING SITE; DRUG BINDING; DRUG SELECTIVITY; HYDROGEN BOND; IC 50; MITSUNOBU REACTION; MOLECULAR DOCKING; NUCLEOPHILICITY; PERSONALIZED MEDICINE; PH; PHARMACOPHORE; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY;

INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; LIGANDS; MOLECULAR DOCKING SIMULATION; OLIGOPEPTIDES; PEPTIDOMIMETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899579958     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500092w     Document Type: Article

References (42)

1. Goodman, S. L.; Picard, M. Integrins as therapeutic targets Trends Pharmacol. Sci. 2012, 33, 405-412
2. Kapp, T. G.; Rechenmacher, F.; Sobahi, T. R.; Kessler, H. Integrin modulators: a patent review Expert Opin. Ther. Pat. 2013, 23, 1273-1295
3. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 2010, 10, 9-22
4. Shattil, S. J.; Kim, C.; Ginsberg, M. H. The final steps of integrin activation: the end game Nat. Rev. Mol. Cell Biol. 2010, 11, 288-300
5. Pierschbacher, M. D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule Nature 1984, 309, 30-33
6. Hynes, R. O. A reevaluation of integrins as regulators of angiogenesis Nat. Med. 2002, 8, 918-921
7. Marelli, U. K.; Rechenmacher, F.; Sobahi, T. R.; Mas-Moruno, C.; Kessler, H. Tumor targeting via integrin ligands Front. Oncol. 2013, 3, 222
8. Aumailley, M.; Gurrath, M.; Müller, G.; Calvete, J.; Timpl, R.; Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett. 1991, 291, 50-54
9. 3 integrin for a new cancer therapy Angew. Chem., Int. Ed. 1997, 36, 1374-1389
10. 3 integrin antagonists J. Med. Chem. 1999, 42, 3033-3040
11. 3 antagonists as novel anticancer agents J. Med. Chem. 2006, 49, 4526-4534
12. Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Stragies, R.; Kessler, H. Probing integrin selectivity: rational design of highly active and selective ligands for the α5β1 and αvβ3 integrin receptor Angew. Chem., Int. Ed. 2007, 46, 3571-3574
13. 5 integrin binders embedding 4-aminoproline residues J. Med. Chem. 2008, 51, 1771-1782
14. 3 integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics J. Med. Chem. 2010, 53, 106-118
15. Corti, A.; Curnis, F. Tumor vasculature targeting through NGR peptide-based drug delivery systems Curr. Pharm. Biotechnol. 2011, 12, 1128-1134
16. 3 integrin as a molecular imaging probe for angiogenesis J. Med. Chem. 2012, 55, 5024-5033
17. 3 J. Med. Chem. 2012, 55, 10460-10474
18. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation Anti-Cancer Agents Med. Chem. 2010, 10, 753-768
19. Reardon, D. A.; Cheresh, D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies Genes Cancer 2011, 2, 1159-1165
20. Merck KGaA press release, February 25, 2013,: http://www.merckgroup.com/ en/media/extNewsDetail.html?newsId=BE2FE07AD630830EC1257B1D001F007B& newsType=1.
21. Bochen, A.; Marelli, U. K.; Otto, E.; Pallarola, D.; Mas-Moruno, C.; Di Leva, F. S.; Boehm, H.; Spatz, J. P.; Novellino, E.; Kessler, H.; Marinelli, L. Biselectivity of isoDGR peptides for fibronectin binding integrin subtypes α5β1 and αvβ6: conformational control through flanking amino acids J. Med. Chem. 2013, 56, 1509-1519
22. Mondal, G.; Barui, S.; Chaudhuri, A. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor Biomaterials 2013, 34, 6249-6260
23. Pfaff, M.; Tangemann, K.; Müller, B.; Gurrath, M.; Müller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αVβ3, and α5β1 integrins J. Biol. Chem. 1994, 269, 20233-20238
24. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human α5β1 integrin: strategies for designing new α5β1 integrin antagonists J. Med. Chem. 2005, 48, 4204-4207
25. Smallheer, J. M.; Weigelt, C. A.; Woerner, F. J.; Wells, J. S.; Daneker, W. F.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds Bioorg. Med. Chem. Lett. 2004, 14, 383-387
26. Heckmann, D.; Meyer, A.; Laufer, B.; Zahn, G.; Stragies, R.; Kessler, H. Rational design of highly active and selective ligands for the α5β1 integrin receptor ChemBioChem 2008, 9, 1397-1407
27. Marinelli, L.; Lavecchia, A.; Gottschalk, K.-E.; Novellino, E.; Kessler, H. Docking studies on αvβ3 integrin ligands: pharmacophore refinement and implications for drug design J. Med. Chem. 2003, 46, 4393-4404
28. Rechenmacher, F.; Neubauer, S.; Polleux, J.; Mas-Moruno, C.; De Simone, M.; Cavalcanti-Adam, E. A.; Spatz, J. P.; Fässler, R.; Kessler, H. Functionalizing αvβ3- or α5β1-selective integrin antagonists for surface coating: a method to discriminate integrin subtypes in vitro Angew. Chem., Int. Ed. 2013, 52, 1572-1575
29. 1- integrins Adv. Mater. 2013, 25, 5869-5874
30. Neubauer, S.; Rechenmacher, F.; Beer, A. J.; Curnis, F.; Pohle, K.; D'Alessandria, C.; Wester, H.-J.; Reuning, U.; Corti, A.; Schwaiger, M.; Kessler, H. Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3 Angew. Chem., Int. Ed. 2013, 52, 11656-11659
31. 3 antagonists. Part 7: 3-Substituted tetrahydro-[1,8]naphthyridine derivatives Bioorg. Med. Chem. Lett. 2004, 14, 1049-1052
32. Stragies, R.; Osterkamp, F.; Zischinsky, G.; Vossmeyer, D.; Kalkhof, H.; Reimer, U.; Zahn, G. Design and synthesis of a new class of selective integrin α5β1 antagonists J. Med. Chem. 2007, 50, 3786-3794
33. Knör, S.; Khrenov, A. V.; Laufer, B.; Saenko, E. L.; Hauser, C. A. E.; Kessler, H. Development of a peptidomimetic ligand for efficient isolation and purification of factor VIII via affinity chromatography J. Med. Chem. 2007, 50, 4329-4339
34. Frank, A. O.; Otto, E.; Mas-Moruno, C.; Schiller, H. B.; Marinelli, L.; Cosconati, S.; Bochen, A.; Vossmeyer, D.; Zahn, G.; Stragies, R.; Novellino, E.; Kessler, H. Conformational control of integrin-subtype selectivity in isoDGR peptide motifs: a biological switch Angew. Chem., Int. Ed. 2010, 49, 9278-9281
35. Rechenmacher, F.; Neubauer, S.; Mas-Moruno, C.; Dorfner, P. M.; Polleux, J.; Guasch, J.; Conings, B.; Boyen, H.-G.; Bochen, A.; Sobahi, T. R.; Burgkart, R.; Spatz, J. P.; Fässler, R.; Kessler, H. A molecular toolkit for the functionalization of titanium-based biomaterials that selectively control integrin-mediated cell adhesion Chem.-Eur. J. 2013, 19, 9218-9223
36. Humphries, M. Integrin structure J. Biochem. Soc. Trans. 2000, 28, 311-339
37. Heckmann, D.; Laufer, B.; Marinelli, L.; Limongelli, V.; Novellino, E.; Zahn, G.; Stragies, R.; Kessler, H. Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity Angew. Chem., Int. Ed. 2009, 48, 4436-4440
38. Ho, C. Y.; Strobel, E.; Ralbovsky, J.; Galemmo, R. A. Improved solution- and solid-phase preparation of hydroxamic acids from esters J. Org. Chem. 2005, 70, 4873-4875
39. 6 J. Nucl. Med. 2013, 54, 1101-1105
40. 3-integrin expression in vivo Acc. Chem. Res. 2009, 42, 969-980
41. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand Science 2002, 296, 151-155
42. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities J. Org. Chem. 1997, 62, 7512-7515